GlassScriptPhysician profile
Nancy L Moya
NPI 1922177831
$1,912.79
in general payments reported to CMS, 2019-2025
23 companies · $222 in 2025
The $222 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $198 · 2021: $213 · 2022: $425 · 2023: $399 · 2024: $332 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $826 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $825.82 |
| Education | $127.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $280.84 | 2022-2024 | |
| Astellas Pharma US INC | $229.70 | 2022-2023 | Veozah |
| Abbvie INC. | $215.62 | 2021-2023 | |
| Novo Nordisk INC | $171.07 | 2020-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $166.20 | 2020-2023 | Mounjaro |
| Insulet Corporation | $123.23 | 2020-2025 | Omnipod |
| Pfizer INC. | $109.34 | 2024-2025 | |
| Medtronic Minimed, INC. | $77.59 | 2019-2020 | |
| Exact Sciences Corporation | $64.59 | 2024-2025 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $63.98 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $60.34 | 2020-2025 | Rexulti |
| Glaxosmithkline, LLC. | $56.97 | 2019-2020 | |
| Gilead Sciences, INC. | $53.81 | 2023-2024 | |
| Angiodynamics, INC. | $50.00 | 2019 | |
| Merck Sharp & Dohme LLC | $31.72 | 2020-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lucid Diagnostics INC. | $28.26 | 2024 | |
| Sunovion Pharmaceuticals INC. | $25.55 | 2020 | |
| Dexcom, INC. | $21.64 | 2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $20.85 | 2024 | |
| Hologic Sales and Service, LLC | $19.14 | 2021 | |
| Bioventus LLC | $18.70 | 2022 | |
| Seqirus USA INC | $12.19 | 2019 | |
| Medtronic, INC. | $11.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Moya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.